国产bbaaaaa片,成年美女黄网站色视频免费,成年黄大片,а天堂中文最新一区二区三区,成人精品视频一区二区三区尤物

首頁(yè)> 美國(guó)衛(wèi)生研究院文獻(xiàn)>Journal of Aerosol Medicine and Pulmonary Drug Delivery >Excipient Enhanced Growth Aerosol Surfactant Replacement Therapy in an In Vivo Rat Lung Injury Model
【2h】

Excipient Enhanced Growth Aerosol Surfactant Replacement Therapy in an In Vivo Rat Lung Injury Model

機(jī)譯：體內(nèi)大鼠肺損傷模型中的賦形劑增強(qiáng)生長(zhǎng)氣霧劑表面活性劑替代療法

代理獲取
本網(wǎng)站僅為用戶提供外文OA文獻(xiàn)查詢和代理獲取服務(wù)，本網(wǎng)站沒(méi)有原文。下單后我們將采用程序或人工為您竭誠(chéng)獲取高質(zhì)量的原文，但由于OA文獻(xiàn)來(lái)源多樣且變更頻繁，仍可能出現(xiàn)獲取不到、文獻(xiàn)不完整或與標(biāo)題不符等情況，如果獲取不到我們將提供退款服務(wù)。請(qǐng)知悉。
  • 摘要
  • 著錄項(xiàng)
  • 相關(guān)主題

摘要

Background: In neonatal respiratory distress syndrome, breathing support and surfactant therapy are commonly used to enable the alveoli to expand. Surfactants are typically delivered through liquid instillation. However, liquid instillation does not specifically target the small airways. We have developed an excipient enhanced growth (EEG) powder aerosol formulation using Survanta?.Methods: EEG Survanta powder aerosol was delivered using a novel dry powder inhaler via tracheal insufflation to surfactant depleted rats at nominal doses of 3, 5, 10, and 20 mg of powder containing 0.61, 0.97, 1.73, and 3.46 mg of phospholipids (PL), whereas liquid Survanta was delivered via syringe instillation at doses of 2 and 4 mL/kg containing 18.6 and 34 mg of PL. Ventilation mechanics were measured before and after depletion, and after treatment. We hypothesized that EEG Survanta powder aerosol would improve lung mechanics compared with instilled liquid Survanta in surfactant depleted rats.Results and Conclusion: EEG Survanta powder aerosol at a dose of 0.61 mg PL significantly improved lung compliance and elastance compared with the liquid Survanta at a dose of 18.6 mg, which represents improved primary efficacy of the aerosol at a 30-fold lower dose of PL. There was no significant difference in white blood cell count of the lavage from the EEG Survanta group compared with liquid Survanta. These results provide an in vivo proof-of-concept for EEG Survanta powder aerosol as a promising method of surfactant replacement therapy.
機(jī)譯：背景： 在新生兒呼吸窘迫綜合征中，通常使用呼吸支持和表面活性劑治療來(lái)使肺泡擴(kuò)張。表面活性劑通常通過(guò)液體滴注給藥。然而，液體滴注并不專門(mén)針對(duì)小氣道。我們使用 Survanta? 開(kāi)發(fā)了一種賦形劑促進(jìn)生長(zhǎng) （EEG） 粉末氣霧劑配方。方法：使用新型干粉吸入器通過(guò)氣管吹氣將 EEG Survanta 粉末氣霧劑以 3、5、10 和 20 mg 粉末的標(biāo)稱劑量輸送到表面活性劑耗盡的大鼠，其中含有 0.61、0.97、1.73 和 3.46 mg 磷脂 （PL），而液體 Survanta 通過(guò)注射器滴注以 2 和 4 mL/kg 的劑量輸送，含有 18.6 和 34 mg PL。測(cè)量耗竭前后的通氣力學(xué)， 和治療后。我們假設(shè)與滴注液體 Survanta 相比，EEG Survanta 粉末氣霧劑會(huì)改善表面活性劑耗盡大鼠的肺力學(xué)。結(jié)果和結(jié)論：與 18.6 mg 劑量的液體 Survanta 相比，劑量為 0.61 mg PL 的腦電圖 Survanta 粉末氣霧劑顯著改善了肺順應(yīng)性和彈性，這代表了氣霧劑在低 30 倍劑量的 PL 下的主要療效得到改善。與液體 Survanta 相比，EEG Survanta 組灌洗液的白細(xì)胞計(jì)數(shù)沒(méi)有顯著差異。這些結(jié)果為 EEG Survanta 粉末氣霧劑作為一種有前途的表面活性劑替代療法方法提供了體內(nèi)概念驗(yàn)證。

著錄項(xiàng)

代理獲取

客服郵箱：kefu@zhangqiaokeyan.com

京公網(wǎng)安備：11010802029741號(hào) ICP備案號(hào)：京ICP備15016152號(hào)-6 六維聯(lián)合信息科技 (北京) 有限公司?版權(quán)所有

  • 客服微信

  • 服務(wù)號(hào)